Sol-Gel Technologies (SLGL) investor relations material

Introduction and agenda

• Agenda covered SGT-610, Gorlin Syndrome Alliance perspectives, Hedgehog signaling, diagnosis and management, clinician views, panel discussion, and Q&A.

• SGT-610 is investigational patidegib gel 2%, a topical Hedgehog-pathway inhibitor intended to prevent BCCs in adults with Gorlin syndrome; it has Orphan Drug and Breakthrough Therapy designations.

KOL background and credentials

• Julie Breneiser of the Gorlin Syndrome Alliance shared her family’s experience, including more than 1,000 BCC removals and repeated surgeries.

• Ervin Epstein discussed Gorlin syndrome biology and Hedgehog signaling; he is a research dermatologist, retired senior scientist, and PellePharm co-founder.

• Kavita Sarin directs Stanford’s Skin Cancer Genetics Program; Elizabeth Billingsley is a dermatology professor and Mohs surgeon. They addressed diagnosis, genetics, surgical burden, and outcomes.

Market insights and analysis

• Gorlin syndrome causes lifelong BCC formation; patients may develop hundreds or thousands of tumors, with repeated procedures contributing to scars, disfigurement, and treatment fatigue.

• Alliance survey: 45% reported over 50 BCCs on the face, neck, and scalp; 42% reported over 50 elsewhere and 5% over 1,000 elsewhere. 94% considered a tolerable preventive treatment reducing new BCCs by 30% an improvement.

• Management estimated 6,100 eligible U.S. patients after exclusions and ~80% adherence; 65% peak penetration implies 4,000 treated patients and $860 million in sales. Pediatric and ex-U.S. patients were excluded.

• The ~$860M peak-sales estimate also cites an 11,000-patient U.S. population and ~$270K expected annual net price; international pricing may be lower and was excluded from the forecast.

• Management cited ~200 centers of excellence and a dedicated field team of ~20 FTEs for a focused U.S. launch; international commercialization may involve partners.